CLINICAL TRIALS PROFILE FOR MAXALT-MLT
✉ Email this page to a colleague
All Clinical Trials for MAXALT-MLT
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00360282 ↗ | Does a Migraine Medication Decrease Rotational Motion Sickness in People Suffering From Migraines? | Completed | Merck Sharp & Dohme Corp. | N/A | 2006-08-01 | The purpose of this study is to determine if Rizatriptan, a migraine medication, lowers motion sickness in migraine sufferers. |
| NCT00360282 ↗ | Does a Migraine Medication Decrease Rotational Motion Sickness in People Suffering From Migraines? | Completed | University of Pittsburgh | N/A | 2006-08-01 | The purpose of this study is to determine if Rizatriptan, a migraine medication, lowers motion sickness in migraine sufferers. |
| NCT00397254 ↗ | Two Rizatriptan Prescribing Portions for Treatment of Migraine | Completed | Merck Sharp & Dohme Corp. | Phase 4 | 2006-12-01 | The primary objective of this study is to evaluate a clinical limit (CL) of rizatriptan (9 rizatriptan 10mg Orally Disintegrating Tablet (ODT) per month) versus (vs.) a formulary limit (FL) of rizatriptan (27 rizatriptan 10mg ODT per month) as measured by the number of days of migraine per month. |
| NCT00397254 ↗ | Two Rizatriptan Prescribing Portions for Treatment of Migraine | Completed | Clinvest | Phase 4 | 2006-12-01 | The primary objective of this study is to evaluate a clinical limit (CL) of rizatriptan (9 rizatriptan 10mg Orally Disintegrating Tablet (ODT) per month) versus (vs.) a formulary limit (FL) of rizatriptan (27 rizatriptan 10mg ODT per month) as measured by the number of days of migraine per month. |
| NCT00471952 ↗ | Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2007-04-01 | The purpose of this study is to evaluate the effect of rizatriptan, alone or combined with caffeine for treating acute attacks of migraine. Each subject will have 3 months to treat 3 acute migraine headache attacks. Each subject will be dispensed one box containing 3 packets of study medication labeled for Headache #1, Headache #2, or Headache #3. Each packet wil contain either Maxalt 10mg MLT or a Maxalt placebo (sugar pill), and a capsule containing either caffeine 75mg or a capsule containing placebo (sugar). One headache will be treated with a combination of Maxalt 10mg MLT and caffeine. Another headache will be treated with a combination of Maxalt 10mg MLT and a capsule containing placebo. A third headache will be treated with just placebo. Neither the subject, the study coordinator, or your study doctor will know in which order you will receive the three different treatments. This information is available in case of emergency. |
| NCT00471952 ↗ | Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache | Completed | Diamond Headache Clinic | Phase 3 | 2007-04-01 | The purpose of this study is to evaluate the effect of rizatriptan, alone or combined with caffeine for treating acute attacks of migraine. Each subject will have 3 months to treat 3 acute migraine headache attacks. Each subject will be dispensed one box containing 3 packets of study medication labeled for Headache #1, Headache #2, or Headache #3. Each packet wil contain either Maxalt 10mg MLT or a Maxalt placebo (sugar pill), and a capsule containing either caffeine 75mg or a capsule containing placebo (sugar). One headache will be treated with a combination of Maxalt 10mg MLT and caffeine. Another headache will be treated with a combination of Maxalt 10mg MLT and a capsule containing placebo. A third headache will be treated with just placebo. Neither the subject, the study coordinator, or your study doctor will know in which order you will receive the three different treatments. This information is available in case of emergency. |
| NCT00719134 ↗ | The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache | Completed | Beth Israel Deaconess Medical Center | Phase 4 | 2008-09-01 | Evidence-based medicine depends on distinguishing between pharmacological effects and placebo effects in randomized controlled trials (RCT). This proposal seeks to rigorously investigate fundamental questions concerning pharmacological effects, placebo effects and their interactions. Relief of symptoms of acute migraine will be the test condition for this scientific experiment because of migraine's evident clinical significance and the possibility of using participants as their own control during sequential acute migraine attacks. Our overall goal is to elucidate how the pharmacological effects of 100 mg rizatriptan (an FDA-proven effective medication for acute migraine) and the effects of placebo treatment can be modified by varied knowledge and/or expectation ("contextual") conditions. Such knowledge has the possibility to suggest potentially more efficient methodologies to test new medications that can be used to augment and enhance the apparatus of the RCT. General Aim: To elucidate and clarify what is a pharmacological effect and what is a placebo effect, how such effects vary in different knowledge/expectations contexts, and mutually constitute one another and interact. General Hypothesis: The measured pharmacological effect of an effective medication (rizatriptan) and the measured effect of placebo treatment are determined significantly by different knowledge/expectations contexts. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for MAXALT-MLT
Condition Name
Clinical Trial Locations for MAXALT-MLT
Trials by Country
Clinical Trial Progress for MAXALT-MLT
Clinical Trial Phase
Clinical Trial Sponsors for MAXALT-MLT
Sponsor Name
